Package 0008-0836-21

{"route": ["ORAL"], "spl_id": "3f8cf689-0fbb-4056-a85d-150dfd527313", "openfda": {"unii": ["7D7RX5A8MO"], "rxcui": ["313581", "313583", "313585", "729929", "729931", "729932"], "spl_set_id": ["53c3e7ac-1852-4d70-d2b6-4fca819acf26"], "manufacturer_name": ["Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0008-0836-21)", "package_ndc": "0008-0836-21", "marketing_end_date": "20260630", "marketing_start_date": "19971101"}], "brand_name": "Effexor XR", "product_id": "0008-0836_3f8cf689-0fbb-4056-a85d-150dfd527313", "dosage_form": "CAPSULE, EXTENDED RELEASE", "pharm_class": ["Norepinephrine Uptake Inhibitors [MoA]", "Serotonin Uptake Inhibitors [MoA]", "Serotonin and Norepinephrine Reuptake Inhibitor [EPC]"], "product_ndc": "0008-0836", "generic_name": "VENLAFAXINE HYDROCHLORIDE", "labeler_name": "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Effexor", "brand_name_suffix": "XR", "active_ingredients": [{"name": "VENLAFAXINE HYDROCHLORIDE", "strength": "150 mg/1"}], "application_number": "NDA020699", "marketing_category": "NDA", "marketing_end_date": "20260630", "marketing_start_date": "19971101"}